Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754377 | 0.86 | HSD17B10 (0.37) | TSHRTDP1SPHK1USP2HTT | |
| SCHEMBL25754384 | 0.86 | SAT1 (0.34) | SMN1; SMN2ALDH1A1TSHRKDM4ESPHK1 | |
| SCHEMBL25754352 | 0.86 | CASP2 (0.36) | SMN1; SMN2TSHRTDP1MEN1KMT2A | |
| SCHEMBL25754383 | 0.83 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1TSHRKDM4EPOLB | |
| SCHEMBL25754369 | 0.82 | ADRB2 (0.31) | HTT | |
| SCHEMBL25754364 | 0.77 | CASP2 (0.34) | SMN1; SMN2TSHRTDP1MEN1KMT2A | |
| SCHEMBL25754231 | 0.76 | USP2 (0.55) | THRBSPHK1USP2MEN1KMT2A | |
| SCHEMBL25754242 | 0.75 | USP2 (0.49) | TDP1THRBSPHK1USP2MEN1 | |
| SCHEMBL1252986 | 0.74 | KDM4E (0.52) | SMN1; SMN2ALDH1A1TSHRKDM4EPOLB | |
| SCHEMBL25754247 | 0.73 | USP2 (0.51) | THRBSPHK1USP2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | SMN1; SMN2 2462/4885ALDH1A1 2539/4885TSHR 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.